Recombinant factor VIIa: Review of current "off license" indications and implications for practice

AACN Advanced Critical Care

Volumn 18, Issue 2, 2007, Pages 141-148

  Rose, Louise ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Hemorrhage; Recombinant factor VIIa; Trauma and coagulopathy

Indexed keywords

BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CONTROL; DRUG LABELING; DRUG MONITORING; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HEART SURGERY; HUMAN; INJURY; INTENSIVE CARE; LIVER FAILURE; METHODOLOGY; MORTALITY; NURSE ATTITUDE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAFETY; TREATMENT OUTCOME; UNITED STATES;

CARDIAC SURGICAL PROCEDURES; CRITICAL CARE; DRUG AND NARCOTIC CONTROL; DRUG LABELING; DRUG MONITORING; ERYTHROCYTE TRANSFUSION; EVIDENCE-BASED MEDICINE; FACTOR VII; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; LIVER FAILURE; NURSE'S ROLE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SAFETY; TREATMENT OUTCOME; UNITED STATES; WOUNDS AND INJURIES;

EID: 34250624476     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/01.AACN.0000269257.06794.40     Document Type: Review

References (63)

1. Gowers C, Parr M. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care. 2005;33:196-200.
2. Mohr A, Holcomb J, Dutton R, Duranteau J. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care. 2005;9(suppl 5):S37-S42.
3. Goodnough L. Treatment of critical bleeding in the future intensive care unit. Intensive Care Med. 2002;28:S221.
4. Erhardtsen E. Ongoing Novoseven trials. Intensive Care Med. 2002;28:S248-S255.
5. Biss T, Hanley J. Recombinant activated factor VII (rFVIIa/NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome. Vox Sang. 2005;90:45-52.
6. Levi M, Peters M, Buller H. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33(4):883-890.
7. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med. 2002;28:S241-S247.
8. Roberts H, Monroe D, White G. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-3864.
9. Grounds R, Bolan C. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in non-trauma settings. Crit Care. 2005;9(suppl 5):S29-S36.
10. Aitken M. Recombinant factor VIIa. Emerg Med Australas. 2004;16:446-455.
11. Robertson J. Prevention of intraventricular haemorrhage: a role for recombinant activated factor VII. J Paediatr Child Health. 2006;42:325-331.
12. Pusateri A, Park M. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care. 2005;9(suppl 5):S15-S24.
13. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003;17:S1-S5.
14. Lisman T, De Groot P. Mechanism of action of recombinant factor VIIa. J Thromb Haemost. 2003;1:1138-1139.
15. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-439.
16. Uhlmann E, Eby C. Recombinant activated factor VII for non-hemophiliac bleeding patients. Curr Opin Haematol. 2004;11:198-204.
17. Clark A, Gordon W, Walker I, Tait R. "Last ditch" use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. 2004;86:120-124.
18. O'Neill P, Bluth M, Gloster E, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without pre-existing coagulopathy. J Trauma Inj Inf Crit Care. 2002;52:400-405.
19. Davis S. Use of Recombinant Factor VIIa in Uncontrollable Haemorrhage: A Position Statement of the NSW Therapeutic Assessment Group Inc. Sydney, Australia: NSW Therapeutic Assessment Group Inc; 2002.
20. O'Connell N, Perry D, Hodgson A, O'Shaughnessey D, Laffan M, Smith O. Recombinant FVIIa in the management of controlled hemorrhage. Transfusion. 2003;43:1 711-1716.
21. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli multidisciplinary rFVIIa taskforce. J Thromb Haemost. 2005;3:640-648.
22. Eikelboom J, Bird R, Blythe D, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis. 2003;14:713-717.
23. Mayo A, Misgav M, Kluger Y, et al. Recombinant activated factor VII (Novoseven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang. 2004;87:34-40.
24. Dutton R, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709-718.
25. Meng Z, Wolberg A, Monroe D, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55:886-891.
26. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879.
27. Lynn M, Jeroukhimov I, Jewelewicz D, et al. Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock. J Trauma. 2002;52:703-707.
28. Martinowitz U, Holcomb J, Pusateri A. Intravenous rFVII administrated for hemorrhage control in hypothermic coagulopathic swine with grade V liver injury. J Trauma. 2001;50:721-729.
29. Boffard K, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double blind clinical trials. J Trauma. 2005;59:8-18.
30. Hyllner M, Houltz E, Jeppson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. European J Cardiothorac Surg. 2005;28:254-258.
31. Nuttall G, Oliver W, Ereth Mea. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology. 2000;92:674-682.
32. Tanaka K, Waly A, Cooper W, et al. Treatment of excessive bleeding in Jehovah's witness patients after cardiac surgery with recombinant factor VIIa (Novoseven). Anesthesiology. 2003;98:1513-1515.
33. Von Heymann C, Hotz H, Konertz W, et al. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesthes. 2002;16:615-616.
34. Karkouti K, Beattie W, Wijeysundera D, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26-34.
35. Lodge J, Jonas S, Jones R, et al. Efficacy and safety of repeated perioperative doses of recombinant VIIa in liver transplantation. Liver Transplant. 2005;11:973-979.
36. Surudo T, Wojicicki M, Milkiewicz PMC, et al. Rapid correction of prothrombin time after low-dose recombinant factor VIIa in patients undergoing orthotopic liver transplantation. Transplant Proc. 2003;35:2323-2325.
37. Hendriks H, van der Maaten J, de Wolf J, Warterbilk T, Slooff M. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anaesthes Analg. 2001;93:287-289.
38. Lodge J, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double blind clinical trial. Anaesthesiology. 2005;102:269-275.
39. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology. 2002;123:118-126.
40. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VII for upper gastrointestinal bleeding in patients with cirrhosis: a randomized double-blind trial. Gastroenterology. 2004;127:1123-1130.
41. Mayer S, Brun N, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral haemorrhage. N Eng J Med. 2005;352:777-785.
42. Mayer S, Brun N, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral haemorrhage. Stroke. 2005;36:74-79.
43. Price G, Kaplan J, Skowronski G. Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a postpartum patient. Br J Anaesth. 2004;93:298-300.
44. Bouwmeester F, Jinkhoff A, Verheijen R, van Geijn H. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstetr Gynecol. 2003;101:1174-1176.
45. Danilos J, Goral A, Paluszkiewicz P, Przesmycki K, Kotarski J. Successful treatment with recombinant factor VIIa for intractable bleeding after pelvic surgery. Obstetr Gynecol. 2003;101:1172-1173.
46. Rott H, Trobisch H, Kretzschmar E. Use of recombinant factor VIIa, Novoseven, in the management of acute haemorrhage. Curr Opin Anaesthes. 2004;17:159-163.
47. Shapiro AD, Gilchrest GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773-778.
48. Ludlam C, Smith M, Morfini M, Gringeri A, Santagostini E, Savidge G. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol. 2003;120:808-813.
49. Loudon B, Smith M. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Int Med J. 2005;35:463-467.
50. Novo Nordisk. NovoSeven Consumer Medicine Information. Novo Nordisk; 2004. Available at: http://www.novonordisk.com.au/media/CMI/ NNNU0089_cmi7_vsl.pdf. Accessed September 28, 2006.
51. Goodnough L, Lublin D, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325-1331.
52. Martinowitz U, Kenet G, Lubetsky A, Luboshitz J, Segal E. Possible role of recombinant activated factor VIIa (rFVIIa in the control of haemorrhage associated with massive trauma. Can J Anaesthes. 2002;49:S15-S20.
53. Sifri Z, Hauser C, Lavery R. Use of recombinant factor VIIa in exsanguinating, coagulopathic trauma patients. J Trauma. 2002;53:1212.
54. Dutton R, Hess J, Scalea T. Recombinant factor VIIa for control of haemorrhage: early experience in critically ill trauma patients. J Clin Anaesth. 2003;15:184-188.
55. Udy A, Vaghela M, Lawton G, Sigston P. The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma. Anaesthesia. 2005;60:613-616.
56. Harrison T, Laskosky J, Jazaeri O, Pasquale M, Cipolle M. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma. 2005;59:150-154.
57. Geeraedts L, Kamphuisen P, Kassjager H, Verwiel J, Van Vugt A, Frolke J. The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma. Inj Int J Care Injured. 2005;36:495-500.
58. Holcomb J, Hoots K, Moore F. Treatment of acquired coagulopathy with recombinant activated factor VII in a damage control patient. Mil Med. 2005;170:287-290.
59. Diprose P, Herbertson M, O'Shaughnessey D, Gill R. Factor VIIa for severe cardiac surgical bleeding. Crit Care. 2002;6(suppl 2):6.
60. Naik V, Mazer C, Latter D, Teitel J, Hare G. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth. 2003;50:599-602.
61. McIlroy D, Silvers A. Recombinant factor VIIa for life-threatening bleeding in high-risk cardiac surgery despite full-dose aprotinin. Anaesth Analg. 2004;99:27-39.
62. Raivio P, Suojaranta-Ylinen R, Kuitunen A. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thoracic Surg. 2005;80:66-71.
63. Romagnoli S, Bevilacqua S, Gelsomino S, et al. Small-dose recombinant activated factor VII (Novoseven) in cardiac surgery. Anaesth Analg. 2006;102:1320-1326.